Outlook Therapeutics (OTLK) investor relations material

Executive summary

• LYTENAVA (bevacizumab gamma) launched commercially in Germany and the UK in June 2025, with expansion into Austria in 2026 and plans for further EU launches; U.S. FDA approval remains pending after multiple Complete Response Letters (CRLs) and ongoing regulatory engagement, including a formal dispute resolution request in April 2026.

• Net loss for the six months ended March 31, 2026 was $27.5 million, with negative net revenue due to increased returns reserves and administrative fees; cash and cash equivalents were $7.7 million at quarter-end.

• There is substantial doubt about the ability to continue as a going concern, with additional financing required to fund operations and commercialization efforts.

Financial highlights

• Six months ended March 31, 2026: net revenue was negative $1.1 million, primarily due to increased returns reserves from lower-than-forecasted sell-through in the UK.

• Research and development expenses decreased by $6.0 million year-over-year, mainly due to lower costs for the NORSE EIGHT clinical trial.

• Selling, general and administrative expenses decreased by $1.8 million year-over-year, driven by lower compensation and professional fees, partially offset by higher European commercial expenses.

• Net cash used in operating activities was $22.8 million for the six months ended March 31, 2026; net cash provided by financing activities was $22.4 million.

Outlook and guidance

• Additional financing is required to fund operations through the next 12 months; management is evaluating licensing, partnerships, equity, and debt options.

• Awaiting FDA decision on the formal dispute resolution request for U.S. approval of ONS-5010/LYTENAVA; if approved, expects 12 years of regulatory exclusivity in the U.S.

• Plans to expand commercial launches in additional EU countries and prepare for potential U.S. launch.